BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05396885 (Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma): BVCT ex-ante prediction vs. reported outcome

On 10 Aug 2024, BioinvestGPT's BVCT predicted technical success and commercial partial success for this trial. The 9 Dec 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially maybe sufficient (non-superior to Carvykti).

Clinical Trial

NCTID
NCT05396885
Acronym
iMMagine-1
Drug Name
Anitocabtagene-autoleucel
Drug MoA
anti-BCMA D-Domain CAR-T cell therapy
Drug Modality
CAR-T therapy
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Relapsed or Refractory Multiple Myeloma
Human Patients
110
Sponsor
Arcellx
Phase
Phase 2

Prediction of , index 1739

Prospective Prediction
Prediction Index
1739
Prediction Date
Commercial Prediction
partial SUCCESS (commercially maybe sufficient clinical benefit in CR/OS non-superior to Carvykti)
Technical Prediction
SUCCESS (statistically significant clinical benefit in ORR/PFS non-superior to Carvykti)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
121 days in advance
Readout Data Interpretation
anito-cell achieved 97% ORR and 62% CR/sCR; non-superior to Carvykti that achieved 98% ORR and 67% sCR
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially maybe sufficient (non-superior to Carvykti)
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase II Study of CART-ddBCMA for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Phase
Phase 2
Status
Active not recruiting
Enrollment
136
Lead sponsor
Kite, A Gilead Company
Conditions
Multiple Myeloma
Interventions
BIOLOGICAL: anitocabtagene-autoleucel
Design
Single group · None
Primary purpose
Treatment
Start
2022-07-15
Primary completion
2026-12
Completion
2026-12
Primary outcomes
  • Overall Response Rate (ORR) (24 Months)

NCT05396885 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials